Get the Stockscreener App
3.43
4.99%
-0.18
Pre-market:
3.49
0.06
+1.75%
Transcode Therapeutics Inc stock is traded at $3.43, with a volume of 95,821.
It is down -4.99% in the last 24 hours and down -54.45% over the past month.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
See More
Previous Close:
$3.61
Open:
$3.61
24h Volume:
95,821
Relative Volume:
1.71
Market Cap:
$2.39M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0129
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-2.83%
1M Performance:
-54.45%
6M Performance:
-87.77%
1Y Performance:
-98.08%
1-Day Range:
$3.33
$3.71
1-Week Range:
$3.33
$4.02
52-Week Range:
$3.21
$236.94
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
3.43 | 2.39M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
TransCode Therapeutics Secures Nasdaq Listing Status After Meeting Critical Requirements - StockTitan
SABBY MANAGEMENT, LLC Acquires Shares in TransCode Therapeutics Inc - GuruFocus.com
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) Short Interest Update - Defense World
Financial Analysis: TransCode Therapeutics (NASDAQ:RNAZ) & Eliem Therapeutics (NASDAQ:ELYM) - Defense World
HC Wainwright Has Optimistic Outlook of RNAZ FY2024 Earnings - Defense World
Analysts Issue Forecasts for RNAZ Q1 Earnings - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
H.C. Wainwright raises TransCode Therapeutics target following SRC go-ahead for Cohort 3 - Investing.com
Clinical Trials News Live Feed - StockTitan
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial - StreetInsider.com
TransCode advances to third patient group in cancer trial - Investing.com India
Dow Surges 150 Points, US Current Account Deficit Widens In Q3 - Benzinga
Transcode announces SRC approved third cohort in TTX-MC138 clinical trial - TipRanks
RNAZTransCode Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Transcode Therapeutics stock hits 52-week low at $6.89 By Investing.com - Investing.com Canada
TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 - MSN
Janux, Vir stocks rally on positive data for Janux drug JANX007 - MSN
TransCode Therapeutics Raises $8M in Private Placement - TipRanks
Why TransCode Therapeutics (RNAZ) Stock Is Diving - Benzinga
TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - The Manila Times
TransCode Therapeutics Announces Reverse Stock Split - TipRanks
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Meet Nasdaq Requirements | RNAZ Stock News - StockTitan
TransCode Therapeutics announces $8M private offering - MSN
Transcode Therapeutics issues 21.2M shares at 37.7c in private placement - Yahoo Finance
TransCode secures $8 million in private placement - Investing.com India
TransCode secures $8 million in private placement By Investing.com - Investing.com Australia
TransCode Therapeutics, Inc. Announces $8 Million Private Placement - The Manila Times
TransCode Therapeutics Secures $8M Private Placement, Issues 21.2M Shares | RNAZ Stock News - StockTitan
TransCode Therapeutics, Inc. announced that it expects to receive $8 million in funding - Marketscreener.com
Transcode Therapeutics announces 1-for-33 reverse stock split - Yahoo Finance
TransCode Therapeutics approves reverse stock split By Investing.com - Investing.com South Africa
TransCode Therapeutics advances with stockholder approvals By Investing.com - Investing.com Canada
TransCode Therapeutics advances with stockholder approvals - Investing.com
TransCode Therapeutics approves reverse stock split - Investing.com
TransCode Therapeutics Announces 1-for-33 Reverse Stock Split to Maintain Nasdaq Listing | RNAZ Stock News - StockTitan
NewAmsterdam Pharma Reports Promising Phase 3 Trial Results - Yahoo Finance
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
TransCode Therapeutics (NASDAQ:RNAZ) Receives Buy Rating from HC Wainwright - Defense World
Craig Hallum Downgrades Sow Good (NASDAQ:SOWG) to Hold - Defense World
The Goldman Sachs Group Boosts Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target to $41.00 - Defense World
TScan Therapeutics (NASDAQ:TCRX) Earns “Buy” Rating from HC Wainwright - Defense World
Sow Good (NASDAQ:SOWG) Lowered to Neutral Rating by Roth Mkm - Defense World
Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World
TransCode Therapeutics Inc (RNAZ) Quarterly 10-Q Report - Quartz
Transcode Therapeutics Reports Increased Losses Amid Funding Challenges - TipRanks
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.08%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):